Spain · AEMPS CIMA
GARDASIL 9 SUSPENSION INYECTABLE EN JERINGA PRECARGADA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 1151007002
- Form
- SUSPENSIÓN INYECTABLE EN JERINGA PRECARGADA
- Composition / generic term
- vacuna anti virus papiloma humano
- Source strength
- 0,5 ml
- Authorisation holder
- Merck Sharp & Dohme B.V.
- Marketed in source snapshot
- Yes
Source-listed ingredients
- VIRUS PAPILOMA HUMANO TIPO 16 PROTEINA L1 — 60 µg
- VIRUS PAPILOMA HUMANO TIPO 6 PROTEINA L1 — 30 µg
- VIRUS PAPILOMA HUMANO TIPO 18 PROTEINA L1 — 40 µg
- VIRUS PAPILOMA HUMANO TIPO 31 PROTEINA L1 — 20 µg
- VIRUS PAPILOMA HUMANO TIPO 11 PROTEINA L1 — 40 µg
- VIRUS PAPILOMA HUMANO TIPO 33 PROTEINA L1 — 20 µg
- VIRUS PAPILOMA HUMANO TIPO 45 PROTEINA L1 — 20 µg
- VIRUS PAPILOMA HUMANO TIPO 52 PROTEINA L1 — 20 µg
- VIRUS PAPILOMA HUMANO TIPO 58 PROTEINA L1 — 20 µg
These values do not establish equivalence or a dose recommendation.
Packages
- GARDASIL 9 SUSPENSION INYECTABLE EN JERINGA PRECARGADA , 1 jeringa precargada de 0,5 ml
Source and coverage
- Professional information (original source)
- Patient leaflet (original source)
- Official document (original source)
Snapshot retrieved: 2026-09-18. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse Spain records →